ArticleInternational journal of molecular sciences2026
Vascular Immune Crosstalk in COVID-19: RAAS Biomarker Signature Linking Angiotensin II to Respiratory Compromise and Soluble ACE2 to IL-13 and FGF, Revealing Therapeutic Targets.
Thais Freitas Barreto Fernandes, Itauá Leston Araujo, Pedro Henrique Oliveira Vianna, Adriana Cesar Bonomo, José Henrique Pilotto, Fernanda Heloise Côrtes, Mariza Gonçalves Morgado, Carmem Beatriz Wagner Giacoia-Gripp, Nathalia Beatriz Ramos De Sá, Marcelo Ribeiro-Alves and 6 more
Abstract read
In one paragraphArticle in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
Thais Freitas Barreto FernandesLaboratório de Aids e Imunologia Molecular, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-900, Brazil.
Itauá Leston AraujoLaboratório de Pesquisa Sobre o Timo, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-900, Brazil.ORCID 0000-0001-7973-512X Pedro Henrique Oliveira ViannaLaboratório de Pesquisa Sobre o Timo, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-900, Brazil.ORCID 0000-0001-8912-8315 Adriana Cesar BonomoLaboratório de Pesquisa Sobre o Timo, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-900, Brazil.
José Henrique PilottoLaboratório de Aids e Imunologia Molecular, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-900, Brazil.ORCID 0000-0003-0521-8597 Fernanda Heloise CôrtesLaboratório de Aids e Imunologia Molecular, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-900, Brazil.ORCID 0000-0003-1416-0657 Mariza Gonçalves MorgadoLaboratório de Aids e Imunologia Molecular, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-900, Brazil.
Carmem Beatriz Wagner Giacoia-GrippLaboratório de Aids e Imunologia Molecular, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-900, Brazil.ORCID 0000-0003-0424-5219 Nathalia Beatriz Ramos De SáLaboratório de Aids e Imunologia Molecular, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-900, Brazil.ORCID 0000-0002-1084-6435 Marcelo Ribeiro-AlvesInstituto Nacional de Infectologia Evandro Chagas, Fiocruz, Rio de Janeiro 21040-900, Brazil.ORCID 0000-0002-8663-3364 Maria Pia Diniz RibeiroInstituto Nacional de Infectologia Evandro Chagas, Fiocruz, Rio de Janeiro 21040-900, Brazil.ORCID 0000-0001-7274-6838 Sandra Wagner CardosoInstituto Nacional de Infectologia Evandro Chagas, Fiocruz, Rio de Janeiro 21040-900, Brazil.
Valdilea G VelosoInstituto Nacional de Infectologia Evandro Chagas, Fiocruz, Rio de Janeiro 21040-900, Brazil.
Beatriz GrinsztejnInstituto Nacional de Infectologia Evandro Chagas, Fiocruz, Rio de Janeiro 21040-900, Brazil.
Roberto Magalhães SaraivaInstituto Nacional de Infectologia Evandro Chagas, Fiocruz, Rio de Janeiro 21040-900, Brazil.ORCID 0000-0002-2263-4261 Dalziza Victalina De AlmeidaLaboratório de Aids e Imunologia Molecular, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-900, Brazil.ORCID 0000-0003-0917-0009 Funding
FAPERJ E-26/200.946/2022Fundação Oswaldo Cruz SEI-25380.001587/2020-20
6 · The paper itselfAbstract
COVID-19 perturbs the renin-angiotensin system (RAAS) and inflammatory pathways, shaping disease severity. Soluble ACE2 (sACE2) and angiotensin II (Ang II) are central regulators of vascular and immune homeostasis. We profiled plasma from COVID-19 patients and controls using ELISA, together with 48 cytokine profiling and clinical data. Both sACE2 and Ang II were significantly elevated in patients. Increased Ang II was associated with oxygen supplementation and dyspnea, and negatively correlated with IL-3, whereas sACE2 correlated with IL-13 and FGF. Comorbidities modulated cytokine expression: diabetes mellitus was linked to reduced LIF and MCP-1, hypertension to decreased LIF and increased IP-10, and obesity to elevated IL-12p70. Age correlated with TNF and HGF, and reduced oxygen saturation was associated with lower LIF. These findings reveal that acute COVID-19 disrupts RAAS and amplifies immune dysregulation, with Ang II emerging as a pivotal mediator of respiratory compromise and inflammatory imbalance, underscoring its potential as a biomarker and therapeutic relevance.
Indexed as
Angiotensin IICOVID-19Fibroblast Growth FactorsInterleukin-13Peptidyl-Dipeptidase ARenin-Angiotensin SystemAngiotensin-Converting Enzyme 2BiomarkersCytokinesFemaleHumansMaleSARS-CoV-2ACE2 protein, humanAngiotensin-Converting Enzyme 2Angiotensin IIBiomarkersCytokinesFibroblast Growth FactorsInterleukin-13Peptidyl-Dipeptidase AACE2Ang IICOVID-19cytokinesSARS-CoV-2
Identifiers
PMID42074217
PMCPMC13115848
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390